Oramed Pharmaceuticals Inc Stock Price, News & Analysis

Oramed Pharmaceuticals has provided a shareholder update highlighting its pivotal Phase 3 oral insulin trial (ORMD-0801) for type 2 diabetes, which is now enrolling patients across multiple U.S. sites. The company has initiated a Phase 2 study for nonalcoholic steatohepatitis (NASH) and plans to begin studies for oral GLP-1 and leptin later in 2021. With a strong financial position, Oramed is in discussions with potential partners to advance its innovative oral delivery technology for diabetes treatment.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) has commenced the randomization of patients for its Phase 3 study of the oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes. The trial, ORA-D-013-1, is recruiting 675 patients across 75 clinical sites in the U.S. to compare ORMD-0801's efficacy against placebo in improving glycemic control. CEO Nadav Kidron emphasized the significance of this FDA-approved study as a global first for oral insulin. Results will be analyzed after the six-month treatment period, focusing on changes in A1c and fasting plasma glucose levels.

Oramed Pharmaceuticals (Nasdaq: ORMP) announced that CEO Nadav Kidron will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on demand starting January 11. Oramed is focused on oral drug delivery systems and aims to revolutionize diabetes treatment with its lead candidate, ORMD-0801, potentially the first commercial oral insulin capsule. Established in 2006, Oramed has completed multiple Phase II clinical trials of ORMD-0801 under FDA regulations.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced positive results from a proof-of-concept study of its oral leptin drug candidate for type 1 diabetes, approved by Israel's Ministry of Health. In this study, ten patients participated, with those receiving the drug showing reduced glucose levels compared to the placebo group. These findings pave the way for a larger double-blind study involving 30 patients. The company aims to tackle rising diabetes rates with its oral leptin treatment, which aligns with the expanding obesity market, projected to reach $15.6 billion by 2024.

Oramed Pharmaceuticals (Nasdaq: ORMP) has initiated a global Phase 2 trial for its oral insulin capsule, ORMD-0801, targeting Nonalcoholic Steatohepatitis (NASH). The trial will include eight clinical sites across the U.S., EU, and Israel, focusing on efficacy measured via MRI-PDFF over a 12-week dosing period. Prior studies indicated a 30% reduction in liver fat with ORMD-0801, fueling optimism for this trial. CEO Nadav Kidron expressed excitement for the international trial and the potential to provide groundbreaking treatment for NASH.

Oramed Pharmaceuticals has initiated its global Phase 3 trials for the oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes (T2D). The screening of the first patients took place at U.S. sites in the ORA-D-013-1 trial, part of a broader two-trial program involving 1,125 patients over 6 to 12 months. The primary goal is to assess ORMD-0801's efficacy against a placebo in glycemic control. CEO Nadav Kidron highlighted the significance of this milestone as the first FDA Phase 3 oral insulin trial.

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) announced a webinar on November 18, 2020, featuring Nobel Laureate Prof. Avram Hershko and Chief Scientific Officer Dr. Miriam Kidron. This session is part of a series focusing on the company's progress in oral drug delivery systems, especially its oral insulin candidate, ORMD-0801, which is entering Phase 3 trials in the U.S. Oramed aims to transform diabetes treatment with its proprietary Protein Oral Delivery (POD™) technology. Interested investors can register for the webinar via a provided link.

Oramed Pharmaceuticals (Nasdaq: ORMP) will have CEO Nadav Kidron present an overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 11:30 AM ET. The company is focused on oral drug delivery systems, aiming to revolutionize diabetes treatment with its lead candidate, ORMD-0801, potentially the first oral insulin capsule. Oramed has completed multiple Phase II trials and is also developing ORMD-0901, an oral GLP-1 analog.

Oramed Pharmaceuticals announced its participation in the AAPS 2020 PharmSci 360 conference, presenting research on its oral insulin candidate, ORMD-0801, for Type 2 diabetes. The presentation, led by Dr. Miriam Kidron, focuses on the glycemic effects of bedtime oral insulin in uncontrolled diabetes patients. Oramed aims to innovate diabetes treatment through its proprietary Protein Oral Delivery (POD™) technology, with ORMD-0801 potentially being the first oral insulin capsule. The company has completed multiple Phase II clinical trials under FDA regulations.